Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02929849 · ClinicalTrials.gov registry record · NA
Satiety and Glucose Indices in Adults
A NA study, sponsored by Rutgers University.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT02929849: Completed NA study, sponsored by Rutgers University.
NCT02929849 is a NA study that has completed, run by Rutgers University. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02929849, a NA study, has completed, sponsored by Rutgers University.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an herb with known alpha-glucosidase inhibitor properties (Salacia Chinensis, SC), affects postprandial appetite ratings and glucose indices in overweight/obese individuals.
Primary Outcome
Visual analog scale (VAS)
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT 300 mg SC
- DIETARY_SUPPLEMENT 500 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-01-01 |
| Phase | NA |
What the finished NCT02929849 record still lists
NCT02929849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02929849 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02929849 about?
NCT02929849 is a clinical study titled "Satiety and Glucose Indices in Adults". The purpose of this study is to determine whether an herb with known alpha-glucosidase inhibitor properties (Salacia Chinensis, SC), affects postprandial appetite ratings and glucose indices in overweight/obese individuals.
What is the current status of trial NCT02929849?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2015-08. Estimated completion is 2017-01-01.
What interventions are being tested in trial NCT02929849?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), 300 mg SC (DIETARY_SUPPLEMENT), 500 mg SC (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02929849?
This trial is sponsored by Rutgers University, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02929849's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia